Ross Durland and colleagues at AM Biotechnologies, LLC in the U.S. propose to develop X-aptamers for detecting and quantifying protein biomarkers for neglected diseases. X-aptamers are modified nucleic acids that tightly bind to specific targets and remain stable at high temperature and humidity. AM Biotech will enhance its process for rapidly identifying X-aptamers that will be integrated into a point-of-care platform for diagnosing many diseases.
Grant ID
GCGH7 - OPP1028829
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Challenge
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
1715754.00
Funding Currency
USD
Funding Amount (in USD)
1715754.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
1715754.00
Co-Funded
False